Elekta and ScandiDos Sign Distributor Agreement for Pre-Treatment Verification Tool for Radiation Therapy

Elekta and ScandiDos AB have entered into a non-exclusive global agreement to distribute ScandiDos’s Delta4PT quality assurance (QA) tool. Delta4PT can be used with Intensity Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) techniques to provide complete pre-treatment QA that ensures that the dose prescribed in treatment plans is delivered accurately and safely to patients.

Crawley United Kingdom — Wednesday, May 25, 2011

“We’re very pleased that Elekta, a true innovator and leader in the radiation oncology industry recognized the value of our ScandiDos Delta4PT QA solution,” says Görgen Nilsson, CEO at ScandiDos. “We hope this is the beginning of an ongoing relationship with Elekta and its customers as they strive to make radiation therapy the safest, most effective tool in the fight against cancer and other serious diseases.”

Delta4PT, used to verify IMRT and arc therapy delivery techniques since 2006, enables clinicians to verify dose delivery without compromises, in 3D; instantly analyze and approve plans; evaluate the clinical significance of deviation; and identify the cause of deviations. The benefits are improved efficiency by increasing the volume of patients that can be treated as well as enhanced verification accuracy – enabling more qualified QA decisions to be made.

The agreement will make Delta4PT accessible to the Elekta customer network, further complementing the Elekta QA solutions portfolio and widening the breadth of choices for its customers.

“As an open source, vendor neutral company, our partnership with ScandiDos ensures that our customers can select QA solutions that best meet their needs and clinical resources,” says Brett North, Marketing Director, Oncology at Elekta.

 

###

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.

Visit Elekta - www.elekta.com

Press Releases

For further information, please contact

Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37
Email: stina.thorman@elekta.com
Time zone: CET: Central European

Michelle Lee, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447
Email: michelle.lee@elekta.com
Time zone: EDT: Eastern Daylight Time